Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.


Clinical Trial Description

This is a Phase 2a multi-center, randomized, double-blind, placebo-controlled parallel-group, 4-arm study with an open-label treatment phase in patients with PSP. This study includes a 6-week Screening Period, a 24-week Double-blind Treatment Period, a 24-week Open label Treatment Period, and a Follow-up Visit 4 weeks post treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04993768
Study type Interventional
Source Transposon Therapeutics, Inc.
Contact
Status Active, not recruiting
Phase Phase 2
Start date October 15, 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT04096651 - Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy N/A
Recruiting NCT02194816 - Modifiable Variables in Parkinsonism (MVP)
Completed NCT00703677 - A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Phase 1/Phase 2
Completed NCT00382824 - Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) N/A
Completed NCT04184063 - Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Phase 2
Recruiting NCT04706234 - Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
Recruiting NCT04472130 - Neurodegenerative Diseases Registry
Recruiting NCT04139551 - Oxford Study of Quantification in Parkinsonism
Completed NCT02734485 - Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy N/A
Completed NCT01110720 - Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Phase 2/Phase 3
Completed NCT01174771 - Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration N/A
Completed NCT00465790 - Research of Biomarkers in Parkinson Disease Phase 0
Completed NCT02460094 - Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Phase 1
Recruiting NCT03225144 - Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Completed NCT03058965 - Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Early Phase 1
Recruiting NCT02605785 - A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy N/A
Completed NCT01353183 - Analysis of the Enteric Nervous System Using Colonic Biopsies N/A
Completed NCT00385710 - Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Phase 2
Recruiting NCT05260151 - Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
Active, not recruiting NCT04658199 - A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Phase 1